Welcome to our dedicated page for Co-Diagnostics SEC filings (Ticker: CODX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Co-Diagnostics, Inc. (NASDAQ: CODX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Co-Diagnostics is a Utah-based molecular diagnostics company whose technologies are used in tests designed to detect and analyze nucleic acid molecules (DNA or RNA), and it files periodic and current reports that describe its financial condition, operations, capital structure and material events.
Through Forms 10-K and 10-Q, investors can review audited and interim financial statements, notes, and management’s discussion of results, including information on revenue, operating expenses, operating loss, net loss, cash and cash equivalents, and non-GAAP measures such as adjusted EBITDA. The company explains in its financial releases how adjusted EBITDA is calculated and why management uses it as a supplemental performance metric alongside GAAP results.
Current reports on Form 8-K document material events such as registered direct offerings of common stock and pre-funded warrants, securities purchase agreements, placement agency agreements, and notifications from the Nasdaq Stock Market regarding listing compliance and grace periods for the $1.00 minimum bid price requirement. Filings also cover matters like the grant of additional time to regain compliance, the intention to cure bid price deficiencies, and the implementation of a reverse stock split approved by shareholders and effected through a certificate of amendment.
Definitive proxy statements on Schedule 14A provide details about shareholder meetings and proposals, including the reverse stock split authorization, voting procedures, and record dates. Together, these filings allow users to track CODX’s capital raising activities, equity structure, governance actions and key risk disclosures directly from primary regulatory documents.
On Stock Titan, CODX filings are updated as they are posted to EDGAR and are accompanied by AI-powered summaries that highlight the main points of lengthy documents such as 10-Ks, 10-Qs, 8-Ks and proxy statements. Users can quickly see what changed, identify new financing agreements or listing updates, and locate information on topics like reverse stock splits or non-GAAP metrics without reading every page, while still having full-text filings available for deeper review.
Co-Diagnostics, Inc. reports that Nasdaq has determined to delist its common stock from The Nasdaq Capital Market because the company has not met the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). Trading in its shares is scheduled to be suspended on January 14, 2026, and the stock is expected to trade on the Pink Limited Information tier of the OTC Market under the symbol CODX.
The company plans to request a hearing before a Nasdaq Hearings Panel and notes that, after a 1-for-30 reverse stock split effective January 2, 2026, its closing bid price has been at or above $1.00 per share. If it maintains at least a $1.00 closing bid for 10 consecutive business days ending January 15, 2026, it will seek a compliance determination and cancellation of the hearing, though there is no assurance it will regain compliance or avoid the trading suspension.
Co-Diagnostics, Inc. (CODX) director equity update: A company director reported the vesting and issuance of 57,499 shares of common stock on 11/23/2025 at a stated price of $0.00, reflecting settlement of previously granted restricted stock units under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan. After this transaction, the director beneficially owns 281,666 shares of common stock and 170,834 restricted stock units. The RSUs referenced stem from awards of 40,000 units on January 17, 2023, 70,000 units on June 12, 2023, 110,000 units on April 26, 2024, and 125,000 units on August 13, 2025, each vesting in six equal installments every six months from their respective commencement dates.
Co-Diagnostics, Inc. reported an insider equity transaction by its Chief Financial Officer, Brian L. Brown. On 11/23/2025, Brown had 134,167 restricted stock units convert into common stock at an exercise price of $0.00. Following this vesting event, he beneficially owned 599,355 shares of Co-Diagnostics common stock directly.
On the same date, 40,723 shares of common stock were sold at a price of $0.35 per share. The filing explains that these shares were sold solely to cover tax withholding obligations related to the vesting of restricted stock units under the company’s long-term incentive plan and did not represent a discretionary trade by Brown.
Co-Diagnostics, Inc. (CODX) president Richard David Abbott reported equity compensation activity in company stock. On November 23, 2025, 56,667 shares of common stock were acquired at $0.00 per share upon vesting of restricted stock units, increasing his directly held common stock to 83,402 shares before subsequent sales.
On the same date, 17,200 shares of common stock were sold at $0.35 per share to cover tax withholding obligations tied to the RSU vesting, a sale described as mandated under the company’s equity incentive plans rather than a discretionary trade. After these transactions, Abbott directly owned 66,202 shares of CODX common stock and 293,771 restricted stock units, which stem from prior awards of 120,000 RSUs granted on April 26, 2024 and 220,000 RSUs granted on August 13, 2025 that vest in six equal installments every six months.
Co-Diagnostics, Inc. (CODX) reported an insider equity transaction by its Chief Executive Officer and director. On 11/23/2025, the CEO acquired 163,333 shares of common stock at $0.00 per share through the vesting and settlement of previously granted restricted stock units. On the same date, 49,575 shares of common stock were sold at $0.35 per share to cover tax withholding obligations related to this RSU vesting, as required under the company’s equity incentive plans.
Following these transactions, the CEO beneficially owned 748,252 shares of common stock directly and held 412,500 restricted stock units, each representing a contingent right to receive one share of common stock, subject to vesting schedules under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan.
Co-Diagnostics, Inc. (CODX)11/23/2025. The reporting person acquired 57,499 shares of common stock at a price of $0.00, reflecting the vesting and settlement of previously granted restricted stock units under the company’s 2015 Long Term Incentive Plan.
After this transaction, the director beneficially owned 271,666 shares of common stock directly and 170,834 restricted stock units. These units come from awards of 40,000, 70,000, 110,000 and 125,000 restricted stock units granted between January 17, 2023 and August 13, 2025, each vesting in six equal installments every six months starting on their respective commencement dates.
Co-Diagnostics, Inc. director reports equity award vesting and share increase. On 11/23/2025, the reporting person acquired 57,499 shares of Co-Diagnostics common stock at a price of $0.00 per share, reflecting the vesting and settlement of restricted stock units. Following this transaction, the director beneficially owns 269,166 shares of common stock directly and 170,834 restricted stock units.
The vested and remaining restricted stock units come from prior awards of 40,000, 70,000, 110,000, and 125,000 units granted between January 2023 and August 2025 under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, which vest in six equal installments every six months starting on their respective commencement dates.
Co-Diagnostics, Inc. (CODX) reported an insider equity transaction by a director on 11/23/2025 on a Form 4 filing. The director acquired 57,499 shares of common stock at a price of $0.00 per share, increasing direct beneficial ownership to 269,166 common shares after the transaction.
The activity reflects the vesting and settlement of restricted stock units granted under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan. These units come from prior awards of 40,000, 70,000, 110,000, and 125,000 restricted stock units, each vesting in six equal installments every six months starting on their respective commencement dates.
Co-Diagnostics, Inc. (CODX) filed its Q3 2025 report, showing a sharp revenue decline and continued losses alongside new financing steps. Q3 revenue was $145,380 (vs. $641,141 a year ago) and net loss was $5.9 million (vs. $9.7 million). For the nine months, revenue was $358,567 (vs. $3.77 million) with a net loss of $21.2 million.
Operating expenses fell to $7.1 million in Q3 (from $10.6 million), reflecting lower legal, stock-based compensation, and personnel costs. Cash and cash equivalents were $11.44 million as of September 30, 2025.
The company raised capital during the period via an at-the-market program and a registered direct offering, and subsequently closed a $7.0 million registered direct deal and established a new ATM program for up to $10.0 million (with a prospectus supplement registering approximately $4.1 million). Management disclosed that substantial doubt exists about CODX’s ability to continue as a going concern over the next 12 months absent additional financing and improved operations.
Co-Diagnostics (CODX) furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The company issued a press release attached as Exhibit 99.1, which includes a non-GAAP financial measure. The disclosures under Items 2.02 and 7.01 are furnished, not filed, and are not subject to Section 18 of the Exchange Act, nor incorporated by reference except as expressly stated.
FAQ
What is the current stock price of Co-Diagnostics (CODX)?
What is the market cap of Co-Diagnostics (CODX)?
